146 related articles for article (PubMed ID: 30269132)
1. The Optimal Timing of Restaging Resection before Introduction of Bacillus Calmette-Guerin Immunotherapy in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
Krajewski W; Zdrojowy R; Dembowski J; Poletajew S; Wróbel M; Łuczak M; Tukiendorf A; Kolodziej A
Urol Int; 2019; 102(1):60-68. PubMed ID: 30269132
[TBL] [Abstract][Full Text] [Related]
2. Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.
Arnaud Q; Sebe P; Colau A; Mouton M; Desgrandchamps F; Masson-Lecomte A; Bessede T; Irani J; Dominique I
Fr J Urol; 2024 Jan; 34(1):102548. PubMed ID: 37980231
[TBL] [Abstract][Full Text] [Related]
3. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
4. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
6. Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes.
Krajewski W; Moschini M; Chorbińska J; Nowak Ł; Poletajew S; Tukiendorf A; Afferi L; Teoh JY; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Cianflone F; Mari A; Di Trapani E; Hendricksen K; Alvarez-Maestro M; Rodríguez-Serrano A; Simone G; Zamboni S; Simeone C; Marconi MC; Mastroianni R; Ploussard G; Laukhtina E; Tully K; Kołodziej A; Krajewska J; Piszczek R; Xylinas E; Zdrojowy R;
World J Urol; 2021 Jul; 39(7):2545-2552. PubMed ID: 33230571
[TBL] [Abstract][Full Text] [Related]
7. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer.
Ferro M; Barone B; Crocetto F; Lucarelli G; Busetto GM; Del Giudice F; Maggi M; Crocerossa F; Cantiello F; Damiano R; Borghesi M; Bove PL; Papalia R; Mari A; Luzzago S; Soria F; Marchioni M; La Civita E; Terracciano D; Mistretta FA; Piccinelli M; Marmiroli A; Russo GI; Schips L; Hurle R; Contieri R; Perdonà S; Del Prete P; Mirone V; Tataru OS; Musi G; Montanari E; de Cobelli O; Vartolomei MD
Urol Oncol; 2022 Nov; 40(11):490.e13-490.e20. PubMed ID: 35676172
[TBL] [Abstract][Full Text] [Related]
8. Second transurethral resection and prognosis of high-grade non-muscle invasive bladder cancer in patients not receiving bacillus Calmette-Guérin.
Angulo JC; Palou J; García-Tello A; de Fata FR; Rodríguez O; Villavicencio H
Actas Urol Esp; 2014 Apr; 38(3):164-71. PubMed ID: 24613147
[TBL] [Abstract][Full Text] [Related]
9. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.
Herr HW; Schwalb DM; Zhang ZF; Sogani PC; Fair WR; Whitmore WF; Oettgen HF
J Clin Oncol; 1995 Jun; 13(6):1404-8. PubMed ID: 7751885
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of ReTURB in high grade T1 primary bladder cancer.
Sanseverino R; Napodano G; Campitelli A; Addesso M
Arch Ital Urol Androl; 2016 Jul; 88(2):81-5. PubMed ID: 27377079
[TBL] [Abstract][Full Text] [Related]
11. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guérin.
Baltacı S; Bozlu M; Yıldırım A; Gökçe Mİ; Tinay İ; Aslan G; Can C; Türkeri L; Kuyumcuoğlu U; Mungan A
BJU Int; 2015 Nov; 116(5):721-6. PubMed ID: 25715815
[TBL] [Abstract][Full Text] [Related]
12. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
13. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
14. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
15. Construction of predictive models for cancer-specific survival of patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: results from a multicenter retrospective study.
Nishiyama N; Kitamura H; Hotta H; Takahashi A; Yanase M; Itoh N; Tachiki H; Miyao N; Matsukawa M; Kunishima Y; Taguchi K; Masumori N
Jpn J Clin Oncol; 2014 Nov; 44(11):1101-8. PubMed ID: 25139163
[TBL] [Abstract][Full Text] [Related]
16. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
[TBL] [Abstract][Full Text] [Related]
17. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
18. Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit.
Krajewski W; Moschini M; Nowak Ł; Poletajew S; Tukiendorf A; Afferi L; Teoh J; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Gozzo A; Mari A; Di Trapani E; Hendricksen K; Alvarez-Maestro M; Serrano AR; Simone G; Zamboni S; Simeone C; Marconi MC; Mastroianni R; Ploussard G; Rajwa P; Laukhtina E; Zdrojowy-Wełna A; Kołodziej A; Paradysz A; Tully K; Krajewska J; Piszczek R; Xylinas E; Zdrojowy R
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33076249
[TBL] [Abstract][Full Text] [Related]
19. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
20. External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin.
Kohjimoto Y; Kusumoto H; Nishizawa S; Kikkawa K; Kodama Y; Ko M; Matsumura N; Hara I
Int J Urol; 2014 Dec; 21(12):1201-7. PubMed ID: 25074295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
